Equity Brief · Healthcare2026-05-20
TMO·Healthcare

Thermo Fisher Scientific Inc

I · AI Analysis

The brief

Thermo Fisher supplies the tools, chemicals, and services that pharmaceutical companies and research labs need to discover drugs, manufacture medicines, and run diagnostic tests. They operate across four segments: Life Sciences Solutions (research reagents and instruments), Analytical Instruments (lab equipment), Specialty Diagnostics (clinical testing products), and Laboratory Products and Biopharma Services (contract manufacturing and research services for drug companies).

Thermo Fisher Scientific is a $166.4 billion life sciences and laboratory equipment company that provides instruments, reagents, diagnostics, and contract manufacturing services to pharmaceutical, biotech, and research customers worldwide [Yahoo Finance]. The company serves as a critical infrastructure provider for drug development, with recent growth driven by expanding bioprocess services, new laboratory facilities in Sweden, and partnerships to manufacture oncology drugs [Yahoo Finance]. Despite solid fundamentals, the stock has significantly underperformed the market over the past year, rising only 8.3% compared to the S&P 500's 25.2% gain [Yahoo Finance].

Thermo Fisher shows solid profitability with moderate leverage, though return on capital and stock performance lag expectations.

The brief AI analysisConfidence 8/10

Sentinellis health

6.8/10

Moderate concerns

Market capitalisation

$166.4B

Revenue (TTM)

$44.6B

Explainers

How we read these numbers

Plain-English guides · no account needed

II · Recent news

What moved

6 stories · ranked by relevance

  • Macro2026-05-20

    Thermo Fisher Scientific Highlights Industry Leadership, Growth Outlook and Long-Term Value Creation at 2026 Investor Day

    Yahoo Finance

  • Macro2026-05-19

    Global Cell Culture Media Market Outlook 2026-2036: Biologics Manufacturing and Cell Therapy Expansion Accelerate Growth for Avantor, Thermo Fisher Scientific, and Lonza Group AG

    Yahoo Finance

  • Macro2026-05-18

    Life Science Instrumentation Market Forecast Report 2025-2031: Expanding Activities in Genomics, Proteomics, and Drug Discovery with Thermo Fisher Scientific, Danaher, Agilent, and Shimadzu Leading

    Yahoo Finance

  • Macro2026-05-18

    Nuvation Bio Sharpens IBTROZI Focus With Thermo Fisher And FDA Steps

    Simply Wall St

  • Macro2026-05-18

    Thermo Fisher Scientific’s PPD Clinical Research Business Expands Bioanalytical Capabilities with New Laboratory in Gothenburg, Sweden

    Yahoo Finance

  • Macro2026-05-18

    Thermo Fisher Deepens Oncology Role With Ibtrozi Manufacturing Milestone

    Simply Wall St

Premium · Free with any account

The stock has badly underperformed the market, gaining only 8.3% over the past year while the S&P 500 rose 25.2%, and is down 24.4% year-to-date versus an 8.1% market gain [Yahoo Finance]. This persistent weakness suggests investor concerns about growth trajectory or valuation.

1 of 4 risks in this report

Risks

4

Opportunities

5

Red flags

1

Leadership

10

9 more findings in the full report — free with any account.

Unlock the full Thermo Fisher Scientific Inc analysis

Create a free account to access the complete AI-generated report with inline citations.

  • 4 risks, 5 opportunities and 1 red flag — each with its source
  • 100+ financial metrics with charts and benchmarks
  • Full news summaries with source links
  • Executive team and compensation details
  • PDF export for offline use
Unlock all 10 findings3 free reports · No credit card

III · Related

You might also read

Same sector · Healthcare — or comparable health

Want this for your watchlist?

Read three companies free. No card.

Get 3 free reports

Produced 20 May 2026, 19:48 UTC

Figures come from company filings and market data. The Sentinellis health score and the wording attached to it are our interpretation of those figures, not numbers the company reported.

Not investment advice and not a recommendation to buy or sell. Sentinellis holds no positions in the companies it covers, takes no payment from issuers, and has no broker referral arrangements.

How every figure and score is calculated